L-NMMA citrate

Synonyms: Methylarginine citrate; Tilarginine citrate
L-NMMA (Tilarginine) citrate 是一种非选择性和竞争性一氧化氮合酶 (nitric oxide synthase) 抑制剂,可抑制 nNOS、eNOS、iNOS 三种亚型以减少 NO 生成,能够缓解机械性异常疼痛、热痛觉过敏和脉络膜纤维化,并可用于伤害感受、骨癌痛及近视相关研究。
产品编号: MS-X34538 CAS No.: 209913-88-2 分子式: C13H24N4O9 分子量: 380.35
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

L-NMMA (Tilarginine) citrate 是一种非选择性和竞争性一氧化氮合酶 (nitric oxide synthase) 抑制剂,可抑制 nNOS、eNOS、iNOS 三种亚型以减少 NO 生成,能够缓解机械性异常疼痛、热痛觉过敏和脉络膜纤维化,并可用于伤害感受、骨癌痛及近视相关研究。

生物实验数据

生物活性 L-NMMA (Tilarginine) citrate is a non-selective and competitive nitric oxide synthase inhibitor that inhibits the three isoforms nNOS, eNOS, and iNOS to reduce NO production, alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis, and can be used in research on nociception, bone cancer pain, and myopia.
体内研究
(In Vivo)

L-NMMA (50 µg; 鞘内注射; 单次给药) citrate 可在给药后 2 h 和 12 h 显著缓解小鼠的骨癌诱导性机械性异常痛觉和热痛觉过敏。
L-NMMA (20 nmol; 玻璃体内注射; 隔日 1 次,2-4 周) citrate 在镜片诱导近视豚鼠中通过抑制 NO 信号通路减轻脉络膜纤维化、延缓近视进展。

Animal Model: C3H/HeJ (male, 4-6 weeks old, 20-22 g, intramedullary inoculation of NCTC 2472 osteosarcoma cells)
Dosage: 50 µg
Administration: i.t.; single administration
Result: Increased paw withdrawal mechanical threshold to 0.90 g at 2 h and 0.63 g at 12 h compared to 0.40 g in vehicle-treated tumor mice.
Increased paw withdrawal thermal latency to 16.2 sec at 2 h and 12.7 sec at 12 h compared to 10.1 sec in vehicle-treated tumor mice.
Lost analgesic effect at 24 h post-administration.
Animal Model: British short-haired tricolor guinea pigs (2-week-old, 110-130 g, lens-induced myopia model)
Dosage: 20 nmol
Administration: intravitreal injection; once every other day; 2 and 4 weeks
Result: Increased refraction significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Reduced the D-value of axial length between the myopic eye and control eye significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Increased choroidal thickness to 80.62 μm at 4 weeks compared to 63.54 μm in the lens-induced myopia group.
Reduced degradation of choroidal pigment particles and narrowed particle gaps compared to the lens-induced myopia group.
Produced denser, more orderly choroidal tissue structure compared to the lens-induced myopia group.
Reduced choroidal fibrosis compared to the lens-induced myopia group.
Lowered gene expression levels of NOS1, NOS3, TGF-β1, COL I, and α-SMA significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Lowered protein levels of NOS1, NOS3, TGF-β1, COL I, and α-SMA significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Reduced expression of COL I, α-SMA, NOS1, NOS3, and TGF-β1 in choroidal tissues compared to the lens-induced myopia group.

化学信息

分子量 380.35
分子式 C13H24N4O9
CAS No. 209913-88-2
别名 Methylarginine citrate; Tilarginine citrate

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础